Hillstream BioPharma Announces Acceptance of Abstract at
Preclinical Update on HSB-510 and navitoclax, a Novel Quatramer™-based, First-in-Class Dual Inhibitor of PI3-Kδ/HDAC6 in combination with navitoclax...
United States Hillstream Quatramer Development Agreement National Center A Cooperative Research Translational Sciences
Source: globenewswire.com